Medscape
The European Medicines Agency (EMA) recommended in its April meetings approval of marketing authorizations for two orphan medicines: Alyftrek for the treatment of cystic fibrosis and Attrogy for the treatment of hereditary transthyretin (TTR)–mediated amyloidosis. Alyftrek, a combination of deutivacaftor, tezacaftor, and vanzacaftor, manufactured by Vertex Pharmaceuticals (Ireland…
Read More
Cystic Fibrosis & Amyloidosis Orphan Drugs Get European Yes
Gaylene Antes
09:19
The European Medicines Agency (EMA) recommended in its April meetings approval of marketing authorizations for two orphan medicines: Alyftrek for the treatment of cystic fibrosis and Attrogy for the treatment of hereditary transthyretin (TTR)–mediated amyloidosis. Alyftrek, a combination of deutivacaftor, tezacaftor, and vanzacaftor, manufactured by Vertex Pharmaceuticals (Ireland…
